Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents
In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R1 = OH, R2 = NHsu
Piatnitski Chekler, Eugene L.,Butera, John A.,Di, Li,Swillo, Robert E.,Morgan, Gwen A.,Rossman, Eric I.,Huselton, Christine,Larsen, Bjarne D.,Hennan, James K.
Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
-
Page/Page column 33-34
(2008/06/13)
More Articles about upstream products of 943134-39-2